Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

By G. Van Assche, M. Van Ranst, R. Sciot, B. Dubois, Severine Vermeire, M. Noman, J. Verbeeck, K. Geboes, W. Robberecht, P. Rutgeerts. New England Journal of Medicine, 2005

963 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/661443492b512c451e12afde386b06251727ed81

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Bryan L. Roth
2. Brian K. Kobilka
3. Arthur Christopoulos
4. M. von Zastrow

In Oncology

1. Brian K. Kobilka

Citations in the corpus

• Functional Selectivity and Classical Concepts of Quantitative Pharmacology (2007, background): “Indeed, antagonists with the ability to induce 5-HT2A receptor down-regulation might be therapeutically useful, for example, for individuals at risk for progressive multifocal leukoencephalopathy as a side effect of treatment with drugs like natalizumab (Engelhardt and Briskin, 2005; Ransohoff, 2005”